Replies to post #93394 on Innovation Pharmaceuticals Inc (IPIX)

[frrol]

If Brilacidin isn't effective broadly enough for Gramm negative, hopefully the company has another HDP that is and can test it, and ultimately commercialize it, as a broad-spectrum ABX cocktail.

[F1ash]

Thanks for the reply.

If I understand SIRS correctly, the prognosis is greatly improved the sooner the antibiotic is administered. The problem is that sometimes it turns out not to be a bacterial infection and with a multi-dose antibiotic the doctors have to decide between continuing with an unnecessary drug or stopping and possibly speeding up resistance.

Looks like the gram negatives may be within Brilacidin's scope as well.

"Active against multiple Gram-positive and Gram-negative bacteria Our defensin mimetics provide potent, broad spectrum activity against multiple Gram-positive bacteria including MRSA, Enterococcus faecium, and Gram-negative bacteria including Eschericia coli, and Klebsiella pneumonia (NDM-1); all of which have become resistant to many antibiotic drugs. "
By the way you are not the first to find this company because of Kevetrin and discover that there is much more in the pipeline.

[To infinity and beyond!]

Flabby post written when tired.

SIRS refers to potential consequences of bacteria floating around in your bloodstream and not staying local, as in a UTI, or pneumonia. The main adverse impact is striking prolonged drops in blood pressure which is a common killer.